Tabula Rasa price target raised to $45 from $41 at Piper Sandler » 14:4905/0705/07/21
Piper Sandler analyst…
Piper Sandler analyst Sean Wieland raised the firm's price target on Tabula Rasa HealthCare to $45 from $41 and keeps a Neutral rating on the shares following the company's "solid" Q1 results. The analyst is encouraged by Tabula's investment in a seasoned sales force, and by the "early momentum these 40 reps have generated in the MedWise segment." However, Wieland remains on the sidelines due to execution risk.
Tabula Rasa HealthCare sees FY21 revenue $336M-$356M, consensus $341.73M » 16:4305/0605/06/21
Sees FY21 adjusted EBITDA…
Sees FY21 adjusted EBITDA $26M-$32M.
Tabula Rasa HealthCare sees Q2 revenue $80.5M-$82.5M, consensus $81.62M » 16:4205/0605/06/21
Sees Q2 adjusted EBITDA…
Sees Q2 adjusted EBITDA $5.5M-$6.5M.
Tabula Rasa HealthCare reports Q1 adjusted EPS (9c), consensus (9c) » 16:4105/0605/06/21
Reports Q1 revenue…
Reports Q1 revenue $76.7M, consensus $76.15M.
|Over a week ago|
Tabula Rasa HealthCare expands COVID-19 services for pharmacies » 08:1604/1304/13/21
Tabula Rasa HealthCare…
Tabula Rasa HealthCare announced an expansion of COVID-19 services for independent and chain pharmacies. TRHC's technology-driven patient engagement solutions will support pharmacists in the administration of and reporting for the COVID-19 vaccine. Through TRHC's PrescribeWellness patient-relationship management solution, community pharmacies can achieve expanded patient reach during the critical, nationwide rollout of the COVID-19 vaccine. Innovative services such as contact-free vaccination management - a virtual, patient-friendly vaccination intake and scheduling tool - enable community pharmacies to engage their patients effectively and safely for the administration of the COVID-19 vaccine and beyond.
|Over a month ago|
Fly Intel: Top five analyst downgrades » 09:5303/0103/01/21
FTI, RMAX, TRHC, BGNE, ZIOP
Catch up on today's…
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. TechnipFMC (FTI) downgraded to Equal Weight at Morgan Stanley with analyst Sasikanth Chilukuru saying if the current market cap of Technip Energies (THNPF) is used, rather than the firm's own fair value estimate, than there is no upside seen for TechnipFMC shares. 2. RE/MAX Holdings downgraded to Neutral from Buy at Compass Point with analyst Matthew Gaudioso saying after appreciating 34% since the company's Q3 earnings call, the stock is now trading slightly above its recent historical multiples. 3. Tabula Rasa HealthCare (TRHC) downgraded to Hold from Buy at Truist with analyst Sandy Draper saying the firm's Buy rating was predicated on steady high teens to 20% growth in CareVention and accelerating growth and margin expansion in the MedWise business, and while CareVention has been "OK," COVID is pressuring census and keeping growth muted. 4. BeiGene (BGNE) downgraded to Underperform from Outperform at CLSA with analyst Tony Ren citing a weaker sales forecast, a higher forecast for R&D spending due to the collaboration with Novartis (NVS), sentiment, and what he sees as a lack of meaningful clinical, regulatory or revenue catalysts for his cut to his rating for BeiGene. 5. Ziopharm (ZIOP) downgraded to Neutral from Buy at H.C. Wainwright with analyst Swayampakula Ramakanth seeing questions on the company's direction following the CEO change. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
Tabula Rasa HealthCare downgraded to Hold from Buy at Truist » 07:2803/0103/01/21
Truist analyst Sandy…
Truist analyst Sandy Draper downgraded Tabula Rasa HealthCare to Hold from Buy with a price target of $42, up from $41. The firm's Buy rating was predicated on steady high teens to 20% growth in CareVention and accelerating growth and margin expansion in the MedWise business, and while CareVention has been "OK," COVID is pressuring census and keeping growth muted, Draper tells investors in a research note. The analyst expects 2022 to improve, but sees more risks than catalysts in 2021.
Tabula Rasa HealthCare downgraded to Hold from Buy at Truist » 06:1703/0103/01/21
Truist analyst Sandy…
Truist analyst Sandy Draper downgraded Tabula Rasa HealthCare to Hold from Buy with a $42 price target.
Tabula Rasa HealthCare downgraded to Neutral from Overweight at Piper Sandler » 17:0402/2402/24/21
Piper Sandler analyst…
Piper Sandler analyst Sean Wieland downgraded Tabula Rasa HealthCare to Neutral from Overweight with a price target of $41, up from $40. Wieland said he lacks conviction in the company's "ability to execute" on what he sees as an "aggressive, and back-half weighted, FY21 guide." The analyst added that he sees headwinds to revenue and adjusted EBITDA targets, and "can't continue to give the company credit for bookings and pipeline successes when conversions seem to be perpetually delayed." Wieland downgrades the stock to Neutral "pending evidence of execution."
Cantor downgrades Tabula Rasa HealthCare to Neutral on 'underwhelming' outlook » 11:2302/2402/24/21
As previously reported,…
As previously reported, Cantor Fitzgerald analyst Steven Halper downgraded Tabula Rasa HealthCare to Neutral from Overweight with an unchanged price target of $40 after the company reported what he called "solid" Q4 results but gave 2021 guidance he called "underwhelming." The company's 2021 revenue guidance implying about 16% year-over-year growth "seems reasonable," but its adjusted EBITDA guidance was "disappointing," said Halper, who has reduced his own adjusted EBITDA estimate following the outlook commentary from the company. He thinks it will be "at least a few quarters" until there is better visibility into 2022, the analyst added.